Doctors, telehealth firms and med spas are flocking to a gray‑market boom in injectable peptides that promise anti‑aging, muscle growth and other wellness benefits. The compounds remain unapproved by the FDA, so they cannot be marketed for human use. Yet health‑policy advocate Robert F. Kennedy Jr. backs a pending reclassification that could legitimize the trade. Analysts estimate the underground trade may generate hundreds of millions annually.

Telehealth platforms are already building the supply chain for a future where compounding pharmacies can dispense experimental peptides safely. In February 2025, Hims and Hers bought a peptide‑compounding plant in Menlo Park, Calif., while digital‑health firm Noom seized Tailor Made Compounding, extending presence to 46 states. Investors see a multibillion-dollar opportunity as the market expands and the industry rapidly consolidates.

With venture capital flowing into clinics and online retailers, the sector faces regulatory risk and potential liability if FDA enforcement intensifies. Nonetheless, the rush signals a shift toward DIY longevity products and could reshape how insurers and employers view preventive health spending. The emerging peptide market now commands close scrutiny from investors and regulators alike.